People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ASLAN Pharmaceuticals Ltd | — | Biotechnology | Series B | $25.0M | $40.5M | 2023 |
Andrew Howden at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Howden on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kathleen M. Metters | 1 | 4 |
| Robert E. Hoffman | 1 | 2 |
| Carl Firth, Ph.D. | 1 | 1 |
| Neil Graham, MBBS, M.D., MPH | 1 | 1 |
| Ben M. Goodger | 1 | 1 |
| Stephen M. Doyle | 1 | 1 |
| Kiran Asarpota | 1 | 1 |
| Alexandre M. Kaoukhov | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.